# ç´°èŒåŸ¹é¤Šå ±å‘Šèˆ‡æŠ—èŒè—¥ç‰©æ„Ÿå—æ€§ (Antimicrobial Susceptibility Testing, AST)

## å®šç¾© (Definition)

- **æŠ—èŒè—¥ç‰©æ„Ÿå—æ€§è©¦é©— (AST)**ï¼šé€éå¯¦é©—å®¤æ–¹æ³•æ¸¬å®šç´°èŒå°å„ç¨®æŠ—èŒè—¥ç‰©çš„æ•æ„Ÿæ€§ï¼Œç”¨æ–¼æŒ‡å°è‡¨åºŠæŠ—ç”Ÿç´ æ²»ç™‚ã€‚  
- å ±å‘Šå½¢å¼é€šå¸¸ä»¥ **SIR** æˆ– **MIC** é¡¯ç¤ºã€‚  

---

## SIR è§£é‡‹ (S, I, R Categories)

- **S (Susceptible / æ˜“æ„Ÿå—)**  
  - ç´°èŒåœ¨æ¨™æº–åŠ‘é‡ä¸‹å°æŠ—ç”Ÿç´ æ•æ„Ÿï¼Œæ²»ç™‚å¯èƒ½æœ‰æ•ˆã€‚  
- **I (Intermediate / ä¸­ä»‹æˆ–åŠ‘é‡ä¾è³´æ€§æ•æ„Ÿ)**  
  - ç´°èŒå°è—¥ç‰©åæ‡‰ä»‹æ–¼æ•æ„Ÿèˆ‡æŠ—è—¥ä¹‹é–“ã€‚  
  - è‡¨åºŠä¸Šå¯èƒ½éœ€è¦ **è¼ƒé«˜åŠ‘é‡** æˆ– **è—¥ç‰©é›†ä¸­æ–¼æ„ŸæŸ“éƒ¨ä½** æ‰æœ‰æ•ˆã€‚  
- **R (Resistant / æŠ—è—¥)**  
  - ç´°èŒå°æŠ—ç”Ÿç´ ä¸æ•æ„Ÿï¼Œå³ä½¿ä½¿ç”¨æ¨™æº–åŠ‘é‡æ²»ç™‚é€šå¸¸ç„¡æ•ˆã€‚  

> ğŸ“Œ è¨»ï¼šè‡ª 2019 å¹´èµ·ï¼ŒCLSI å°‡ I çš„å®šç¾©æ”¹ç‚º **ã€ŒSusceptible, Increased exposureã€**ï¼Œæ„æŒ‡åœ¨å¢åŠ åŠ‘é‡æˆ–å»¶é•·è¼¸æ³¨æ™‚é–“ä¸‹ä»å¯èƒ½æœ‰æ•ˆã€‚  

---

## MIC (Minimum Inhibitory Concentration, æœ€ä½æŠ‘èŒæ¿ƒåº¦)

- **å®šç¾©**ï¼šæŠ‘åˆ¶ç´°èŒå¯è¦‹ç”Ÿé•·çš„æœ€ä½æŠ—èŒè—¥ç‰©æ¿ƒåº¦ï¼ˆé€šå¸¸ä»¥ Î¼g/mL è¡¨ç¤ºï¼‰ã€‚  
- **è‡¨åºŠåˆ¤è®€**ï¼š  
  - å°‡ MIC å€¼èˆ‡æ¨™æº–åŒ–æ–·é» (breakpoints, CLSI/EUCAST) æ¯”è¼ƒï¼Œæ±ºå®šå±¬æ–¼ Sã€I æˆ– Rã€‚  
  - ä¾‹ï¼šæŸèŒæ ªå° Ceftriaxone çš„ MIC = 0.5 Î¼g/mLï¼›è‹¥ CLSI æ–·é»ç‚º S â‰¤1 Î¼g/mLï¼Œå‰‡æ­¤èŒå±¬æ–¼ **S**ã€‚  

---

## è‡¨åºŠæ‡‰ç”¨ (Clinical Application)

1. **æŠ—ç”Ÿç´ é¸æ“‡**ï¼šä¾ AST å ±å‘ŠæŒ‘é¸æœ€åˆé©è—¥ç‰©ã€‚  
2. **åŠ‘é‡èª¿æ•´èˆ‡ MIC å»ºè­°å€¼**ï¼š  
   - **Ceftriaxone**ï¼šMIC â‰¤1 Î¼g/mL â†’ Sï¼›è‹¥ MIC æ¥è¿‘ 1ï¼Œå»ºè­°è¶³é‡ä½¿ç”¨ã€‚  
   - **Piperacillin-tazobactam**ï¼šMIC â‰¤16 Î¼g/mL â†’ Sï¼›æ¥è¿‘ 16 æ™‚å»ºè­°å»¶é•·è¼¸æ³¨ã€‚  
   - **Carbapenems (Meropenem, Imipenem)**ï¼šMIC â‰¤1 Î¼g/mL â†’ Sï¼›è‹¥ MIC=2ï¼Œè€ƒæ…®é«˜åŠ‘é‡/å»¶é•·è¼¸æ³¨ã€‚  
   - **Vancomycin (é‡å° MRSA)**ï¼šMIC â‰¤2 Î¼g/mL ç‚º Sï¼Œä½† MIC â‰¥2 æ™‚è‡¨åºŠæ²»ç™‚å¤±æ•—ç‡å‡é«˜ï¼Œå»ºè­°æ”¹ç”¨ Linezolid æˆ– Daptomycinã€‚  
   - **Aminoglycosides (Gentamicin, Amikacin)**ï¼šéœ€é” **Cmax/MIC â‰¥8â€“10** æ‰æœ‰æ•ˆã€‚  
3. **æ„ŸæŸ“ç®¡åˆ¶**ï¼šé«˜æ¯”ä¾‹ R å ±å‘Šæç¤ºå¯èƒ½çš„è€è—¥èŒæ ªæµè¡Œï¼Œéœ€åŠ å¼·é™¢å…§æ„ŸæŸ“æ§åˆ¶ã€‚  
4. **è—¥ç‰©ç›£æ¸¬çµåˆ (TDM)**ï¼šéƒ¨åˆ†æŠ—èŒåŠ‘ï¼ˆå¦‚ Aminoglycosides, Vancomycinï¼‰éœ€åŒæ™‚è€ƒæ…®è¡€ä¸­æ¿ƒåº¦èˆ‡ MICï¼Œç¢ºä¿ **AUC/MIC æˆ– Cmax/MIC** æ¯”å€¼é”åˆ°æ²»ç™‚æ•ˆæœã€‚  

---

## å ±å‘Šç¯„ä¾‹ (Example Report)

ç§‘å®¤: A6â€ƒNo: 250901038737â€ƒ**æª¢é«”: BLOOD (CVP)**  
æ¡æª¢: 2025/09/01 17:48â€ƒç™»å…¥: 2025/09/01 18:51â€ƒæœ€å¾Œå ±å‘Š: 2025/09/06 11:32  
é¡¯ç¤ºè—¥æ•è©¦é©—ï½œé›»å­ç—…æ­·  

**Blood Culture #1**: Staphylococcus capitis - Time To Positive: 85.23 hrs  

| Antibiotic | S/I/R | MIC (Î¼g/mL) | Note |
|------------|-------|-------------|------|
| CC: Clindamycin | R | â‰¥4 | |
| CIP: Ciprofloxacin | R | â‰¥8 | |
| DAP: Daptomycin | S | 1 | |
| E: Erythromycin | R | â‰¥8 | |
| FA: Fusidic acid | R | 16 | |
| GM: Gentamicin 10 Î¼g | R | â‰¥16 | |
| LVX: Levofloxacin | R | 4 | |
| LZD: Linezolid | S | 2 | |
| OX: Oxacillin | R | â‰¥4 | |
| SXT: Trimethoprim/sulfamethoxazole | S | 20 | |
| TE: Tetracycline | R | â‰¥16 | |
| VA: Vancomycin | S | â‰¤0.5 | |

> **è‡¨åºŠæç¤º**ï¼šè«‹åƒè€ƒè—¥æ•çµæœèª¿æ•´æŠ—ç”Ÿç´ ã€‚  

**è¨»è§£**  

- S: Susceptible  
- I: Intermediate  
- R: Resistant  
- SDD: Susceptible-dose dependent  
- WT: Wild type  
- non-WT: non-wild type  
- ç©ºç™½: æ²’æœ‰åˆ¤è®€æ¨™æº–  
- Cefazolin (urine): é©ç”¨æ–¼å–®ç´”æ€§æ³Œå°¿é“æ„ŸæŸ“  
- Cefazolin (others): é©ç”¨æ–¼å…¶ä»–æ„ŸæŸ“  

---

## ç¸½çµ (Summary)

- **AST** æ˜¯æ„ŸæŸ“æ²»ç™‚çš„é‡è¦ä¾æ“šã€‚  
- **SIR åˆ†é¡** å¹«åŠ©å¿«é€Ÿè§£è®€æŠ—èŒè—¥ç‰©æœ‰æ•ˆæ€§ã€‚  
- **MIC** æä¾›æ›´ç²¾ç¢ºæ•¸æ“šï¼Œé ˆçµåˆæ¨™æº–æ–·é»èˆ‡è‡¨åºŠåŠ‘é‡è©•ä¼°ã€‚  
- å ±å‘Šåˆ¤è®€æ‡‰ç¶œåˆ **æ„ŸæŸ“éƒ¨ä½ã€è—¥ä»£å‹•åŠ›å­¸/è—¥æ•ˆå­¸ (PK/PD)** èˆ‡ **ç—…äººé«”æ³**ï¼Œè€Œéåƒ…ä¾æ•¸å€¼æ±ºå®šã€‚  

---

## åƒè€ƒæ–‡ç» (References)

1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. 33rd ed. Wayne, PA: CLSI; 2023.  
2. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, 2023. Available at: https://www.eucast.org.  
3. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline. *Am J Health Syst Pharm*. 2020;77(11):835-864. doi:10.1093/ajhp/zxaa036.  
